$HROW Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

on January 23, 2023 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

on January 5, 2023 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

on January 5, 2023 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
HROW
Source:
Read more

$HROW Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

on December 21, 2022 News and Tags: , , , with 0 comments
Time:
7:21 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Secures Capital to Close Recently Announced Acquisition

on December 16, 2022 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Secures Capital to Close Recently Announced Acquisition

on December 16, 2022 News and Tags: , , , with 0 comments
Time:
5:00 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:30 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Prices $25 Million Offering

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:31 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:32 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:30 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Prices $25 Million Offering

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:31 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

on December 14, 2022 News and Tags: , , , with 0 comments
Time:
4:32 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow and iOR Partners Expand National Product Supply Agreement

on November 30, 2022 News and Tags: , , , with 0 comments
Time:
6:00 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Announces Third Quarter 2022 Financial Results

on November 14, 2022 News and Tags: , , , with 0 comments
Time:
2:05 PM
Symbol:
HROW
Source:
Read more

$HROW Harrow Launches Atropine.com

on November 10, 2022 News and Tags: , , , with 0 comments
Time:
6:00 AM
Symbol:
HROW
Source:
Read more

$HROW Harrow Launches Atropine.com

on November 10, 2022 News and Tags: , , , with 0 comments
Time:
6:00 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Sells Non-Ophthalmic Compounding Business

on October 5, 2022 News and Tags: , , , with 0 comments
Time:
5:35 PM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

on September 29, 2022 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

on September 27, 2022 News and Tags: , , , with 0 comments
Time:
1:50 PM
Symbol:
HROW
Source:
Business Wire
Read more

$HROW Harrow Health Announces Second Quarter 2022 Financial Results

on August 9, 2022 News and Tags: , , , with 0 comments
Time:
4:01 PM
Symbol:
HROW
Source:
Business Wire
Read more